Clinical Cancer Research, Vol 4, Issue 9 2125-2128, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients

J Geisler, SB Geisler, PE Lonning, R Smaaland, KM Tveit, H Refsum and PM Ueland
Department of Oncology, Haukeland University Hospital, Bergen, Norway.

We measured plasma total homocysteine (tHcy) in 14 patients (13 patients with colorectal cancer and 1 patient with breast cancer) during their first treatment with 5-fluorouracil (5-FU) plus leucovorin [LV (5-FULV)]. Eight of these patients were investigated a second time after 3-10 cycles (median, 4 cycles) with 5-FULV. Each cycle consisted of two administrations of 5-FU (500 mg/m2) and LV (60 mg/m2) given 24 h apart. The first administration of 5-FULV on day 1 of the first cycle induced a rapid reduction of the tHcy level from 12.5 micromol/liter (10.4-15.1 micromol/liter; geometric mean with 95% confidence interval of the mean) to 9.1 micromol/liter (7.5-11.1 micromol/liter) in 24 h. tHcy remained stable at this level after the second administration of 5-FULV. In addition, the 5-FULV regimen caused a concurrent 4-fold increase in both serum and erythrocyte folate. The fifth cycle with 5-FULV had only marginal effects on the tHcy level. 5-FU without LV modulation had no effect on the plasma tHcy or folate status in eight breast cancer patients. Our data establish the reduction of tHcy as a responsive indicator of LV pharmacodynamics.

This article has been cited by other articles:

				J. E. Goodman, J. A. Lavigne, K. Wu, K. J. Helzlsouer, P. T. Strickland, J. Selhub, and J. D. Yager COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk Carcinogenesis, October 1, 2001; 22(10): 1661 - 1665. [Abstract] [Full Text] [PDF]